AbbVie (ABBV)

AbbVie presents results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting (ABBV) 42.90 +0.21 : Co announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL). Results from the study were presented at ASCO. This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in patients with relapsed/refractory CLL and NHL. 

"The ABT-199 data underscore AbbVie's commitment to the development of treatments for some of the hardest-to-treat cancers like CLL and NHL. Early trials of ABT-199 have shown the compound's potential in these hematological malignancies, which support the continuation of its clinical development program."

CLL
Preliminary efficacy results showed that 46 of 55 patients (84%) achieved a response to ABT-199. Specifically, ten patients (18%) achieved a complete response (CR) or complete response with incomplete bone marrow recovery and 36 patients (65%) achieved a partial response (PR). The study also demonstrated a response in patients with high-risk markers. A partial response was achieved by 13 of 16 patients with deletion of the short arm of chromosome 17 (17p deletion) and 14 of 18 patients with fludarabine-refractory CLL. Later stage clinical trials are expected. 

NHL
Preliminary efficacy results showed 17 of 32 patients (53%) achieved an overall response rate (ORR), with one patient experiencing a complete response and 15 patients experiencing a partial response. Studies are ongoing.

 ** daily **

 ** weekly **